Healthcare / BiotechnologyBSE
$17.52
-0.03 (-0.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-156.1M · quality 62.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
9/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$757M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-18.9%
↓Gross Margin
5.4%
↓Debt/Equity
0.80
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2023 · 1 años de histórico normalizado
Revenue CAGR
-43.1%
FCF CAGR
—
FCF margin
24.4%
FCF / Net income
-0.65x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $446.1M · net income $-166.4M · FCF $108.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2023 | 2022 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $446.1M | $446.1M | $783.9M |
| Net Income | $-166.4M | $-166.4M | $-87.5M |
| EBITDA | $-151.1M | $-151.1M | $-43.7M |
| EPS | -3.85 | -3.85 | -2.03 |
| Gross Margin | 5.4% | 5.4% | 15.7% |
| Operating Margin | -35.9% | -35.9% | -6.2% |
| Net Margin | -37.3% | -37.3% | -11.2% |
| Balance Sheet | |||
| Debt/Equity | 0.80 | 0.80 | 0.74 |
| Current Ratio | 0.33 | 0.33 | — |
| Cash Flow | |||
| Free Cash Flow | $108.9M | $108.9M | $-421.2M |
| Returns | |||
| ROE | -18.9% | -18.9% | -8.3% |
| Valuation | |||
| P/B | 0.86 | 0.86 | — |
| Growth & Yield | |||
| Revenue Growth | -43.1% | -43.1% | — |
| EPS Growth | -89.7% | -89.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-34.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.03 → -3.85
Residual
-34.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.